The Safety and Efficacy of Absnow Fully Biodegradable Atrial Septal Defect Occluder: A Prospective, Single‐Center Phase III Clinical Trial
Clinical Cardiology · 2026-02 · 49 (2)
DOI: 10.1002/clc.70262 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Cardiology, online erschienen am 04.02.2026. Verfasst von Shiqiang Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Heart Septal Defects, Atrial, Septal Occluder Device, Absorbable Implants, Cardiac Catheterization. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Projects, Guangdong Provincial High-Level Key Specialty.
Abstract (Originalsprache)
Objective
To evaluate the safety, short‐term and mid‐term occlusion performance of the Absnow fully biodegradable atrial septal occluder in pediatric patients.
Background
The Absnow Occluder, an innovative fully biodegradable closure for ASD, has shown its safety and effectiveness in initial animal studies and preclinical trials.
Methods
As one of the participating multicenter research institutions, our organization conducted interventional closure procedures on 10 pediatric patients with atrial septal defects employing the Absnow fully biodegradable occluder between November 2018 and May 2019. Subsequently, we conducted a clinical follow‐up spanning 4 years.
Results
The immediate success rate of the operation was 100% (10/10). The effective closure rates at immediate, 1 day, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, and 4 years post‐operation were, respectively, 100%, 90%, 100%, 100%, 100%, 100%, 80%, 80%, and 70%. The cumulative incidence of complications at 1 year, 2 years, 3 years, and 4 years post‐operation were 0%, 20%, 20%, and 30%, respectively. No severe complications, such as device dislodgment, high‐degree atrioventricular block, or vascular complications, occurred during the 4‐year follow‐up. Nevertheless, two patients experienced substantial residual shunting due to occluder degradation or umbrella displacement, and underwent further intervention.
Conclusion
This study further confirmed the short‐to‐mid‐term safety and acceptable efficacy of the Absnow fully biodegradable atrial septal occluder based on a 4‐year follow‐up. The late‐occurring residual shunts with device degradation have an important impact on its long‐term efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
ORCID-Profile: Shiqiang Fan
Förderung
- Shenzhen Science and Technology Projects
- Guangdong Provincial High-Level Key Specialty
Zitieren
APA
Fan, S., Xie, Y., Ou, Z., Liang, P., Wang, W., Li, M., Liu, C., & Li, B. (2026). The Safety and Efficacy of Absnow Fully Biodegradable Atrial Septal Defect Occluder: A Prospective, Single‐Center Phase III Clinical Trial. Clinical Cardiology, 49(2). https://doi.org/10.1002/clc.70262
Vancouver
Fan S, Xie Y, Ou Z, Liang P, Wang W, Li M, et al. The Safety and Efficacy of Absnow Fully Biodegradable Atrial Septal Defect Occluder: A Prospective, Single‐Center Phase III Clinical Trial. Clinical Cardiology. 2026;49(2). doi:10.1002/clc.70262
BibTeX
@article{Fan2026,
author = {Fan, Shiqiang and Xie, Ying and Ou, Zhenheng and Liang, Piaohong and Wang, Wei and Li, Meng and Liu, Cong and Li, Boning},
title = {The Safety and Efficacy of Absnow Fully Biodegradable Atrial Septal Defect Occluder: A Prospective, Single‐Center Phase III Clinical Trial},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {2},
doi = {10.1002/clc.70262}
}
EUVIMED